Building a New Asset-Centric Small Molecule Development Company

In 2013 we embedded with a local private company that had developed best-in-class small molecule screening capabilities for biotech and pharma clients. Their work validating the technology had created a unique collection of proprietary assets. We evaluated 50 distinct assets and their target pathways and defined a portfolio that could be spun out into a new asset-centric drug development company. Each asset was evaluated in the context of the competitive landscape, the attractiveness of the therapeutic hypothesis and disease area, and the ability to develop tractable medchem and preclinical programs. The screening company then used this information to raise an 11MM USD seed round from private investors. We served in the role executive consultant and acting CSO in order to launch and enable all company operations, leading to four programs launched and prosecuted for preclinical development.